A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06545331

Title field or adapter rule

{'original_value': 'A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:27.263692+00:00

Published At

2026-10-30T00:00:00+00:00

Record Updated At

2026-10-30

Source Retrieved At

2026-10-31T22:19:00.066997+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Locally Advanced or Metastatic Solid Tumors", "Esophageal Squamous Cell Cancer", "Head and Neck Squamous Cell Cancer", "NSCLC (Non-small Cell Lung Cancer)", "Hormone-receptor-positive Breast Cancer", "Triple Negative Breast Cancer (TNBC)"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-30", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06545331"

protocolSection.identificationModule.officialTitle

"A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Locally Advanced or Metastatic Solid Tumors (protocolSection.conditionsModule.conditions)
• Esophageal Squamous Cell Cancer (protocolSection.conditionsModule.conditions)
• Head and Neck Squamous Cell Cancer (protocolSection.conditionsModule.conditions)
• NSCLC (Non-small Cell Lung Cancer) (protocolSection.conditionsModule.conditions)
• Hormone-receptor-positive Breast Cancer (protocolSection.conditionsModule.conditions)
• Triple Negative Breast Cancer (TNBC) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['XB010 + Pembrolizumab Dose Escalation Cohorts', 'XB010 Single-Agent Dose Escalation Cohorts', 'XB010 Single-Agent Dose Expansion Cohorts'], 'description': 'IV administration of XB010', 'name': 'XB010', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['XB010 + Pembrolizumab Dose Escalation Cohorts'], 'description': 'IV administration of Pembrolizumab', 'name': 'Pembrolizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• XB010 (protocolSection.armsInterventionsModule.interventions[].name)
• Pembrolizumab (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.